Current ReportESPI 14/2025

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland (“Company”) entered into the register of entrepreneurs of the National Court Register kept by the District Court for Kraków Śródmieście in Krakow, XI Commercial Division of the National Court Register under the KRS number: 0000367359, acting pursuant to art. 399 § 1, art. 402¹ and art. 402² of the Commercial Companies Code, hereby gives a notice that Annual General Meeting of Shareholders will be held on June 26^th, 2025, 12:00 PM, at ul. Leona Henryka Sternbacha 2 in Cracow.

Agenda:

1. Opening of the meeting.
2. Election of the Chairperson of the Meeting.
3. Determination by the Chairperson of the correctness of the Assembly’s convening and its ability to adopt resolutions.
4. Adoption of the agenda.
5. Assessment of the Supervisory Board’s report for the 2024 fiscal year including the evaluation of the Company’s financial statements for the 2024 fiscal year, the Management Board’s report on the Company’s activities for the 2024 fiscal year and the Management Board’s proposal to cover the loss for the 2024 fiscal year.
6. Assessment and approval of the Management Board’s report on the Company’s activities for the 2024 fiscal year.
7. Assessment and approval of the Company’s financial statements for the 2024 fiscal year.
8. Adoption of a resolution on covering the loss for the 2024 fiscal year.
9. Adoption of resolutions on granting discharge to members of the Company’s Management Board and Supervisory Board.
10. Adoption of a resolution on expressing an opinion on the report on remuneration of members of the Company’s Management Board and Supervisory Board for the 2024 financial year.
11. Closing of the meeting.

Further information is also available on the Company’s website at:

https://ryvu.com/investors-media/reports/

 

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 56.1.2 of the Act on Offerings

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Krzysztof Brzózka – Vice President of the Management Board